Abstract: ［Abstract］〓Objective〖HTSS〗〓To explore the effects of liraglutide on score of Montreal Cognitive Assessment(MoCA), urine albumincreatinine ratio(ACR) and urinary podocalyxin(PCX) in patients with type 2 diabetic mild cognitive impairment.
〖HTH〗〖WTHZ〗Methods〖HTSS〗〓 Eighty patients with type 2 diabetic mild cognitive impairment were collected and randomly divided into control group(n=40) and liraglutide group(n=40). Premixed insulin was administrated in control group for 24 weeks while liraglutide in liraglutide group. The systolic blood pressure(SBP), diastolic blood pressure(DBP), hemoglobin A1c(HbA1c), fasting plasma glucose(FPG), total cholesterol(TC), triglyceride(TG), urine ACR and urine PCX of were measured and compared before the treatment and 24 weeks after the treatment. Patients cognitive function was assessed by MoCA.
〖HTH〗〖WTHZ〗Results〖HTSS〗〓There were no significant difference in FBG, HbA1c, SBP, DBP, TG, and TC between two groups before the treatment and 24 weeks after the treatment, while there was no significant change in FBG, HbA1c, SBP, DBP, TG, and TC after the treatment in the two groups(P＞005). Before the treatment, there were no significant difference in the core of MoCA, urine ACR and PCX between two groups(P＞0.05). After the treatment, there were no significant change in the core of MoCA, urine ACR and PCX as compared with that before treatment in control group(P＞0.05), while the core of MoCA in liraglutide group were significantly higher(P＜005) and urine ACR and PCX lower than that before treatment(P＜005). At 24 weeks after the treatment, the core of MoCA in liraglutide group was significant higher （P＜005）and urine ACR and PCX were significant lower than that of control group（P＜005）.
〖HTH〗〖WTHZ〗Conclusion〖HTSS〗〓Liraglutide maybe improve cognitive function and reduce urine ACR and PCX in patients with type 2 diabetic mild cognitive impairment.

Key words: diabetes mellitus, type 2, mild cognitive impairment, liraglutide